These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35476113)

  • 21. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review.
    Boguszewski CL; Korbonits M; Artignan A; García AM; Houchard A; Ribeiro-Oliveira A; de Herder WW
    Endocrine; 2023 Mar; 79(3):527-536. PubMed ID: 36369434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada.
    Cheung WY; LaForty C; Liovas A; McKechnie H; Loree JM
    Pancreas; 2022 Oct; 51(9):1146-1152. PubMed ID: 37078938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
    Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
    J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
    Gurel MH; Han Y; Stevens AL; Furtado A; Cox D
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):22. PubMed ID: 28372573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors.
    Darden C; Price M; Ray D; Goldstein G; Goss D; Bennett L; Garbinsky D; Thota R
    J Patient Rep Outcomes; 2021 Sep; 5(1):82. PubMed ID: 34491454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
    Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
    Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Saif MW; Fu J; Smith MH; Weinstein B; Relias V; Daly KP
    J Pancreat Cancer; 2018; 4(1):64-71. PubMed ID: 30788459
    [No Abstract]   [Full Text] [Related]  

  • 33. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
    Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
    J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
    Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
    Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors.
    Saif MW; Parikh R; Ray D; Kaye JA; Kurosky SK; Thomas K; Ramirez RA; Halfdanarson TR; Beveridge TJR; Mirakhur B; Nagar SP; Soares HP
    J Gastrointest Oncol; 2019 Aug; 10(4):674-687. PubMed ID: 31392048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L; Dubé P; Rinke A
    Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
    Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
    Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.